Key Takeaway: Precision BioSciences, a clinical stage gene editing company, will release its financial results for the second quarter of 2023 on August 4, 2023. The company focuses on ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies. This announcement highlights the company's commitment to transparency and progress in its clinical developments.
Price reaction · baseline $17.388 (2023-08-01 close) · hit after-hours · 2 other DTIL headline(s) in the window, move may be shared
day 0 close
-5.3%
day 1
-7%
day 3 · peak
-8.5%
Market Sentiment Analysis
POSITIVE FACTORS
Precision BioSciences is progressing with its clinical stage gene editing.
The company is set to report its financial results, indicating transparency.
ARCUS-based therapies show potential in gene editing and CAR T treatments.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
DURHAM, N.C. –(BUSINESS WIRE)–Aug. 1, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it will publish financial results for the second quarter 2023
Frequently Asked Questions
When will Precision BioSciences report its Q2 results?
Precision BioSciences will report its second quarter results on August 4, 2023.
What therapies is Precision BioSciences developing?
The company is developing ARCUS-based in vivo gene editing and ex vivo CAR T therapies.